CN119233829A - 用于预防、抑制或治疗伴随假性过敏反应的症状的医药组合物 - Google Patents

用于预防、抑制或治疗伴随假性过敏反应的症状的医药组合物 Download PDF

Info

Publication number
CN119233829A
CN119233829A CN202380041406.1A CN202380041406A CN119233829A CN 119233829 A CN119233829 A CN 119233829A CN 202380041406 A CN202380041406 A CN 202380041406A CN 119233829 A CN119233829 A CN 119233829A
Authority
CN
China
Prior art keywords
acetamide
sulfamoylphenyl
phenyl
chlorophenyl
pyrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380041406.1A
Other languages
English (en)
Chinese (zh)
Inventor
松冈功
伊藤政明
吉田一贵
今井利安
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
School Legal Representative Takasaki University Of Health And Welfare
Nippon Chemiphar Co Ltd
Original Assignee
School Legal Representative Takasaki University Of Health And Welfare
Nippon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by School Legal Representative Takasaki University Of Health And Welfare, Nippon Chemiphar Co Ltd filed Critical School Legal Representative Takasaki University Of Health And Welfare
Publication of CN119233829A publication Critical patent/CN119233829A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380041406.1A 2022-03-31 2023-03-30 用于预防、抑制或治疗伴随假性过敏反应的症状的医药组合物 Pending CN119233829A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2022060261 2022-03-31
JP2022-060261 2022-03-31
PCT/JP2023/013084 WO2023190826A1 (ja) 2022-03-31 2023-03-30 偽アレルギー反応に伴う症状の予防若しくは抑制又は治療用の医薬組成物

Publications (1)

Publication Number Publication Date
CN119233829A true CN119233829A (zh) 2024-12-31

Family

ID=88202752

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380041406.1A Pending CN119233829A (zh) 2022-03-31 2023-03-30 用于预防、抑制或治疗伴随假性过敏反应的症状的医药组合物

Country Status (7)

Country Link
US (1) US20260000678A1 (https=)
EP (1) EP4501357A1 (https=)
JP (1) JPWO2023190826A1 (https=)
CN (1) CN119233829A (https=)
AU (1) AU2023244778A1 (https=)
CA (1) CA3246964A1 (https=)
WO (1) WO2023190826A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025205829A1 (ja) * 2024-03-26 2025-10-02 国立研究開発法人国立循環器病研究センター 脳動脈瘤の予防又は治療用の医薬組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2397480T3 (da) 2009-02-16 2013-09-02 Nippon Chemiphar Co Diazepindionderivat
JP6207399B2 (ja) 2012-01-13 2017-10-04 日本ケミファ株式会社 Ｐ２ｘ４受容体拮抗剤
EP3020707B1 (en) 2013-07-12 2019-08-21 Nippon Chemiphar Co., Ltd. P2x4 receptor antagonist
AU2015296135A1 (en) 2014-08-01 2017-02-16 The Johns Hopkins University MrgprX2/MrgprB2 expressing cell based assay to detect pseudo-allergic drug reactions and to identify blockers to prevent the adverse reactions
US20180338980A1 (en) 2015-06-10 2018-11-29 Bayer Pharma Aktiengesellschaft Aromatic sulfonamide derivatives
PL3458443T3 (pl) 2016-05-03 2021-03-08 Bayer Pharma Aktiengesellschaft Aromatyczne pochodne sulfonamidowe
CA3186937A1 (en) 2020-08-03 2022-02-10 Isao Matsuoka Pharmaceutical composition for preventing, suppressing, or treating symptoms associated with allergic reaction

Also Published As

Publication number Publication date
WO2023190826A1 (ja) 2023-10-05
US20260000678A1 (en) 2026-01-01
JPWO2023190826A1 (https=) 2023-10-05
CA3246964A1 (en) 2025-07-09
AU2023244778A1 (en) 2024-10-17
EP4501357A1 (en) 2025-02-05

Similar Documents

Publication Publication Date Title
CN1898209A (zh) 葡糖激酶调节剂吡啶羧酸衍生物
US8927540B2 (en) Pyridazinone derivatives
CN1934100A (zh) 取代喹唑啉或吡啶并嘧啶衍生物
CN101039677A (zh) 利用a2b腺苷受体拮抗剂预防和治疗气道重建及肺部炎症的方法
CN1575284A (zh) 作为激酶抑制剂的取代的三唑二胺衍生物
CN1886377A (zh) 用作葡糖激酶(glk)激活剂的苯甲酰基氨基吡啶基羧酸衍生物
CN1568185A (zh) 影响葡糖激酶的化合物
CN1471393A (zh) 神经性和神经心理性疾病的治疗方法
CN1711094A (zh) Src家族非受体酪氨酸激酶抑制剂和吉西他滨的组合产品
CN1845734A (zh) 苯并咪唑衍生物及其作为蛋白激酶抑制剂的用途
CN1535266A (zh) 用作mGluR2拮抗剂Ⅱ的二氢-苯并[b][1,4]二氮杂�-2-酮衍生物
CN101039915A (zh) 用于治疗ⅱ型糖尿病和肥胖症的苯氧基苯甲酰胺化合物
CN1056879A (zh) 吡咯衍生物及其制备方法
CN1625555A (zh) 喹唑啉化合物
CN1882588A (zh) A2b腺苷受体拮抗剂
CN1856327A (zh) Vegf受体抑制剂与化疗剂的组合
CN1503793A (zh) N-取代的非芳基-杂环nmda/nr2b拮抗剂
CN1898205A (zh) 吲哚满酮衍生物及其在治疗疾病状态如癌症中的用途
AU2005220911A1 (en) Ion channel modulators
CN1794994A (zh) 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
CN1942445A (zh) 作为jack3激酶调节剂的新的喹啉－甲酰胺类化合物
CN1166361C (zh) 用于控制绝经热潮红的降钙素基因有关肽的拮抗剂及其释出的抑制剂
CN1784232A (zh) 包含抗血管生成剂和Src抑制剂的联合的治疗药物及其治疗用途
CN1890219A (zh) 用作葡糖激酶(glk)激活剂的苯甲酰基氨基吡啶基羧酸衍生物
EP4501357A1 (en) Pharmaceutical composition for preventing or suppressing or treating symptoms accompanying pseudo-allergic reactions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination